17th Mar 2022 07:00
RNS Number : 0575F
Midatech Pharma PLC
17 March 2022
17 March 2022
Midatech Pharma PLC
("Midatech" or the "Company")
Exercise of Warrants and Issue of Equity
Total Voting Rights
Midatech Pharma PLC (AIM: MTPH.L; Nasdaq: MTP), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, announces that it has received a notice of exercise of warrants over 26 ordinary shares of 0.1p each in the Company ("Ordinary Shares") at an exercise price of £10.00 per share.
Application will be made for the admission of the 26 new Ordinary Shares to trading on the AIM Market of the London Stock Exchange plc ("Admission"), which is expected to become effective at 8.00 a.m. on or around 22 March 2022. The new Ordinary Shares will rank pari passu with the existing Ordinary Shares.
The Company's issued share capital following Admission will comprise 98,468,413 Ordinary Shares each with voting rights. The Company does not hold any shares in treasury. This figure of 98,468,413 may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.
For more information, please contact:
Midatech Pharma PLC | |
Stephen Stamp, CEO, CFO | |
Tel: +44 (0)29 2048 0180 | |
www.midatechpharma.com | |
| |
Strand Hanson Limited (Nominated and Financial Adviser) | |
James Dance / Matthew Chandler / Rob Patrick | |
Tel: +44 (0)20 7409 3494 | |
| |
Turner Pope Investments (TPI) Limited (Broker) | |
Andrew Thacker / James Pope (Corporate Broking) Tel: +44(0)20 3657 0050 | |
IFC Advisory Limited (Financial PR and UK Investor Relations) | |
Tim Metcalfe / Graham Herring | |
Tel: +44 (0)20 3934 6630 | |
Email: [email protected] | |
| |
Edison Group (US Investor Relations) Alyssa Factor Tel: +1 (860) 573 9637 Email: [email protected] | |
About Midatech Pharma PLC Midatech Pharma PLC (dual listed on LSE AIM: MTPH; and NASDAQ: MTP) is a drug delivery technology company focused on improving the bio-delivery and bio-distribution of medicines. The Company combines approved and development medications with its proprietary and innovative drug delivery technologies to provide compelling products that have the potential to powerfully impact the lives of patients. The Company has developed three in-house technology platforms, each with its own unique mechanism to improve delivery of medications to sites of disease. All of the Company's technologies have successfully entered human use in the clinic, providing important validation of the potential for each platform: · Q-Sphera™ platform: a disruptive micro-technology used for sustained release to prolong and control the release of therapeutics over an extended period of time (from weeks to months). · MidaSolve™ platform: an innovative nanotechnology used to dissolve insoluble drugs so that they can be administered in liquid form directly and locally into tumours. · MidaCore™ platform: a leading-edge nanotechnology used for targeting medications to sites of disease. The platform nature of the technologies offers the potential to develop multiple drug assets rather than being reliant on a limited number of programmes. Midatech's technologies are supported by 36 patent families including 120 granted patents and an additional 70 patent applications. Midatech's headquarters and R&D facility is in Cardiff, UK. For more information, please visit www.midatechpharma.com |
|
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
[email protected] or visit
www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy.
END
IOEEAFDKFFSAEAA
Related Shares:
MTPH.L
